New cancer clinical trial: Safety and Efficacy of Vicriviroc (MK-7690) in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Microsatellite Stable (MSS) Colorectal Cancer (CRC) (MK-7690-046)

Published on: August 15, 2018 at 12:00PM
Condition:   Colorectal Neoplasms
Interventions:   Drug: Vicriviroc;   Biological: Pembrolizumab
Sponsor:   Merck Sharp & Dohme Corp.
Not yet recruiting
https://ift.tt/2Br8MmT